ESR1 and triple-negative breast carcinoma: Previous studies have reported that ER-positive breast cancers generally demonstrate lower rates of pathologic complete response (pCR) to neoadjuvant chemotherapy compared with HER2-positive or triple-negative breast cancers [20,21].